TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an announcement.
Everest Medicines Limited has announced its unaudited interim results for the first half of 2025, which have been reviewed by its audit committee and auditors, Ernst & Young. The results, available in both Chinese and English, are accessible on the company’s and the Stock Exchange’s websites, with printed versions to be distributed to shareholders by the end of September 2025. This announcement underscores the company’s commitment to transparency and compliance with the Hong Kong Stock Exchange’s listing rules, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$61.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of transformative pharmaceutical products. The company operates primarily in the healthcare industry, targeting unmet medical needs in the Asian market.
Average Trading Volume: 7,511,362
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.97B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.